Exhibit 99.1
|
|
|
|
|
FOR IMMEDIATE RELEASE
May 30, 2024 |
Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory
Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding Company
PALO ALTO, CALIFORNIA
May 30, 2024 (GLOBE NEWSWIRE) - Scilex Holding Company (Nasdaq: SCLX, Scilex or the Company), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today sends a letter to both the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority regarding illegal
market manipulation of the common stock of Scilex.
The practice of manipulative or abusive naked short selling or maintaining naked
short positions may constitute a violation of SEC Regulation SHO. Scilex Management is determined to combat manipulative and illegal short selling of Scilex common stock which has the effect of reducing shareholder value and infringing on
shareholders rights.
A copy of each of the letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority can
be download here.
For more information on Scilex Holding Company, refer to www.scilexholding.com
For more information on ZTlido® including Full Prescribing Information, refer to
www.ztlido.com.
For more information on ELYXYB®, including Full Prescribing Information,
refer to www.elyxyb.com.
For more information on Gloperba®, including Full Prescribing
Information, refer to www.gloperba.com.
About Scilex Holding Company
Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing
non-opioid pain management products for the treatment of acute and chronic pain. Scilex targets indications with high unmet needs and large market opportunities with
non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Scilexs commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the FDA) for the relief of neuropathic pain associated
with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved,
ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and
(iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults, expected to launch in the
first half of 2024.
Page | 1